# Plasma microRNA biomarkers for lung cancer diagnosis

> **NIH NIH UH3** · BIOTARGET DX LLC · 2024 · $169,004

## Abstract

Project Summary-Abstract
 Because the early detection of lung cancer by low-dose CT (LDCT) can reduce the mortality,
annual LDCT screening is now being reimbursed by Centers for Medicare & Medicaid Services
(CMS) for smokers insured through Medicare. However, more than one-quarter of screens
discover indeterminate pulmonary nodules (PNs). 4% of PNs are early-stage lung cancers, while
the remaining 96% are benign. Therefore, LDCT has over-diagnosis. There is an unmet need for
a reflex test for LDCT follow-up to focus care on the 4% smokers need it. The objective of this
project is to develop and validate a plasma test for differentiating malignant from benign PNs at
baseline LDCT. Future use of this test for discriminating between malignant and benign PNs will
complement LDCT for lung cancer detection by reducing the over-diagnosis, and eventually
decrease the deaths and cost.

## Key facts

- **NIH application ID:** 11327683
- **Project number:** 7UH3CA251139-05
- **Recipient organization:** BIOTARGET DX LLC
- **Principal Investigator:** Feng Jiang
- **Activity code:** UH3 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $169,004
- **Award type:** 7
- **Project period:** 2020-09-17 → 2027-03-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/11327683

## Citation

> US National Institutes of Health, RePORTER application 11327683, Plasma microRNA biomarkers for lung cancer diagnosis (7UH3CA251139-05). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/11327683. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*